<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630353</url>
  </required_header>
  <id_info>
    <org_study_id>H-200-002</org_study_id>
    <nct_id>NCT04630353</nct_id>
  </id_info>
  <brief_title>A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer</brief_title>
  <official_title>A Phase 0 Trial of HB-201 for Subjects With Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or With Locally Advanced Cervical Cancer Treated With Chemotherapy and Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hookipa Biotech GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hookipa Biotech GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Window Of Opportunity clinical trial will examine the immunologic effects of the study&#xD;
      agent HB-201 in the head and neck or cervical cancer, when administered either by IT&#xD;
      injection or by IV route.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The window of opportunity, Study H-200-002, will examine the effects of study agent (HB-201)&#xD;
      on subjects during the &quot;window&quot; between diagnosis of their cancer and their definitive cancer&#xD;
      surgery or chemoradiation.&#xD;
&#xD;
      The study will be a 2-arm study design. In Arm 1, the study will enroll subjects with&#xD;
      resectable stage I-III human papillomavirus 16 positive (HPV 16+) genotype squamous cell&#xD;
      cancer of the oropharynx who are candidates for transoral surgery. Participants will receive&#xD;
      a single dose of the study agent HB-201 prior to transoral surgery. Arm 1 will consist of 2&#xD;
      Cohort groups; Cohort 1 will enroll subjects receiving HB-201 as an intratumoral injection&#xD;
      and Cohort 2 will enroll patients receiving HB-201 administered intravenously.&#xD;
&#xD;
      In Arm 2, the study will enroll cervical cancer subjects who have locally advanced squamous&#xD;
      cell carcinoma, adenocarcinoma, and/ or adenosquamous cell carcinoma with HPV 16+ genotype.&#xD;
      Subjects with advanced/metastatic disease that are previously untreated who are planning to&#xD;
      undergo upfront chemoradiation for local control are eligible and will receive an&#xD;
      intratumoral injection of HB-201 prior to the start of chemoradiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response profiles in subjects with HPV 16+ Head and Neck and cervical cancer.</measure>
    <time_frame>Approximately 6-8 weeks</time_frame>
    <description>Measurement of antigen-specific CD8+ T cells in blood and tissue (E7E6 antigen specific assay).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic response comparing IV and IT administration.</measure>
    <time_frame>Approximately 6-8 weeks</time_frame>
    <description>Measurement of antigen-specific CD8+ T cells in blood and tissue (E7E6 antigen specific assay).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of messenger RNA and expression profiles in tumor specimens using RNA-sequencing (800 genes).</measure>
    <time_frame>Approximately 6-8 weeks</time_frame>
    <description>Pre and post administration of HB-201</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor mutational burden (TMB, MSI) in tumor specimens using whole exome sequencing.</measure>
    <time_frame>Approximately 6-8 weeks</time_frame>
    <description>Pre and post administration of HB-201</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure TH1/TH2 proinflammatory cytokines (mesoscale multiplex discovery assay) to characterize metabolic / proteomic changes in serum / plasma</measure>
    <time_frame>Approximately 6-8 weeks</time_frame>
    <description>Pre and post administration of HB-201</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure ctDNA to characterize changes in circulating tumor by NextGen sequencing.</measure>
    <time_frame>Approximately 6-8 weeks</time_frame>
    <description>Pre and post administration of HB-201</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize t-cell receptor repertoire diversity and clonality, by t-cell receptor sequencing.</measure>
    <time_frame>Approximately 6-8 weeks</time_frame>
    <description>Pre and post administration of HB-201.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evidence of response to HB-201</measure>
    <time_frame>Approximately 6-8 weeks</time_frame>
    <description>Change in tumor size per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile of HB-201</measure>
    <time_frame>Approximately 30 days post HB-201 administration</time_frame>
    <description>Number and type of adverse events per CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>HB-201 Intratumorally on Day 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB-201 Intravenously on Day 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB-201 Intratumorally 7 to 14 days before chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cervical cancer who have locally advanced squamous cell carcinoma with HPV 16+ genotype.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 IT</intervention_name>
    <description>Cohort 1: HB-201 given IT, one (1) time, on day 1.</description>
    <arm_group_label>HB-201 Intratumorally on Day 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 IV</intervention_name>
    <description>Cohort 2: HB-201 given IV, one (1) time, on day 1.</description>
    <arm_group_label>HB-201 Intravenously on Day 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB-201 IT</intervention_name>
    <description>HB-201 will be administered IT, one (1) time, 7 to 14 days prior to definitive chemoradiation.</description>
    <arm_group_label>HB-201 Intratumorally 7 to 14 days before chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Confirmed HPV 16+ (human papilloma virus 16 positive) genotype testing of cancer.&#xD;
&#xD;
          -  Disease-free for â‰¥ 2 years from other curatively treated cancers, with&#xD;
             protocol-defined exceptions.&#xD;
&#xD;
          -  Evaluated by cardiologist and/or neurologist if protocol-defined cardiac or&#xD;
             neurological event within the last 6 months.&#xD;
&#xD;
        HPV 16+ Oropharynx Cancer (Arm 1 Cohorts 1 and 2)&#xD;
&#xD;
          -  Newly diagnosed, squamous cell carcinoma or undifferentiated carcinoma of the&#xD;
             oropharynx, determined to be resectable.&#xD;
&#xD;
          -  AJCC v8.0 Tumor, Node, Metastasis (TNM) stage I-III, cT1- T3, and cervical nodes N1-N3&#xD;
             based on clinical or radiographic criteria with no evidence of distant metastases.&#xD;
&#xD;
          -  No prior radiation above the clavicles.&#xD;
&#xD;
          -  Must have acceptable renal and hepatic function as defined per protocol.&#xD;
&#xD;
          -  Cohort 2 (intratumoral administration) only: must have a safe and accessible tumor&#xD;
             lesion amenable for biopsy and IT administration.&#xD;
&#xD;
        HPV 16+ Cervical Cancer (Arm 2)&#xD;
&#xD;
          -  Newly diagnosed, histologically confirmed advanced cervical cancer (squamous cell&#xD;
             carcinoma, adenocarcinoma, or adenosquamous cell carcinoma): International Federation&#xD;
             of Gynecology and Obstetrics (FIGO) clinical stages IB to IVB with plan for initial&#xD;
             treatment of definitive chemoradiation (platinum agent weekly with radiotherapy) for&#xD;
             either curative intent or control of local (pelvic) disease.&#xD;
&#xD;
          -  No prior radiation to the abdomen or pelvis.&#xD;
&#xD;
          -  Must have a safe and accessible tumor lesion amenable for biopsy and IT&#xD;
             administration.&#xD;
&#xD;
          -  Must have normal organ and marrow function as defined per protocol.&#xD;
&#xD;
          -  Must not have a known allergy to cisplatin, carboplatin, or compounds of similar&#xD;
             biologic composition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects:&#xD;
&#xD;
          -  Treatment with any systemic anticancer therapy within 3 years (unless agreed otherwise&#xD;
             between the Sponsor and the Investigator).&#xD;
&#xD;
          -  Treatment with any chronic immunosuppressive medication within 6 months (unless agreed&#xD;
             otherwise between the Sponsor and Investigator).&#xD;
&#xD;
          -  Uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          -  Live vaccine within 28 days (unless agreed otherwise between Sponsor and&#xD;
             Investigator).&#xD;
&#xD;
          -  Known diagnosis of acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          -  Positive Hepatitis B or Hepatitis C tests indicating acute or chronic infection.&#xD;
&#xD;
          -  Intercurrent illness likely to interfere with protocol therapy.&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Female subjects of childbearing potential who do not agree to the use of highly&#xD;
             effective contraception per protocol.&#xD;
&#xD;
          -  Male subjects with sexual partners of childbearing potential who do not agree to the&#xD;
             use of protocol-defined contraception&#xD;
&#xD;
        HPV 16+ Oropharynx Cancer (Arm 1 Cohorts 1 and 2)&#xD;
&#xD;
        â€¢ Primary tumor or nodal metastasis fixed to the carotid artery, skull base, or cervical&#xD;
        spine.&#xD;
&#xD;
        HPV 16+ Cervical Cancer (Arm 2)&#xD;
&#xD;
          -  Treatment with chemotherapy for cervical cancer, prior to planned chemoradiation.&#xD;
&#xD;
          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Hookipa Biotech GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>General Hookipa Contact</last_name>
    <phone>+43 1 890 6360</phone>
    <email>office@hookipabiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hookipa Backup Contact</last_name>
    <phone>+1 332 207 4590</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Center Clinical Trials Office</last_name>
      <phone>414-805-8900</phone>
      <email>CCCTO@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart J Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Bradley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Zenga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aditya Shreenivas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Campbell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Stadler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Becky Massey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Oropharynx Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Intratumoral</keyword>
  <keyword>Intravenous</keyword>
  <keyword>Lymphocytic Choriomeningitis Virus</keyword>
  <keyword>Medical College of Wisconsin Cancer Center</keyword>
  <keyword>Medical College of Wisconsin</keyword>
  <keyword>Transoral Surgery</keyword>
  <keyword>Window of Opportunity</keyword>
  <keyword>HPV 16+</keyword>
  <keyword>HPV 16+ head and neck squamous cell cancer</keyword>
  <keyword>HPV 16 E7E6</keyword>
  <keyword>E7E6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

